Regulus Therapeutics, Inc. RGLS shares were initially trading higher Monday before pulling back and turning negative after the company announced topline results from its study related to the treatment of autosomal dominant polycystic kidney disease (AKPD).
What Happened: The results from the Phase 1B MAD clinical trial of RGLS8429 which Regulus announced Monday before the market opened, demonstrating a decrease in htTKV and an increase in PC1 and PC2. PC1 and PC2 are proteins known to inversely correlate with disease severity.
“We are pleased to see the consistent mechanistic response and reduction in htTKV at the 3mg/kg dose level of RGLS8429,” said president and head of research and development Preston Klassen, M.D.
Additionally, the treatment was well tolerated across participants.
Related Link: Yidu Finds Good Medicine In Regulatory Nod For Its AI
RGLS Price Action: Regulus Therapeutics shares are down 20.3% at $2.00 at the time of writing per Benzinga Pro.
Image: 428338 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
